News
New diagnostic biomarkers and new therapeutic targets for the minority disease Lymphangioleiomyomatosis
A study by IDIBELL and the ICO, with the collaboration of the Spanish LAM Association, has detected that patients suffering from Lymphangioleiomyomatosis have elevated plasma levels of a histamine derivative, which could be used for the diagnosis of the disease.
An international study with IDIBELL participation associates new genetic and immunological defects with severe COVID-19
TLR7 gene is essential for shaping response mechanisms to the virus and having deficiencies can lead to severe cases of SARS-CoV-2 in young people. The presence of autoantibodies against type I interferons increases with age and it is confirmed that it would increase the severity of COVID-19 in people older than 70 years.
Dr. Sebastiano Biondo obtains the position of Professor of Surgery at the University of Barcelona
Dr. Sebastiano Biondo, head of the Digestive Tube Pathology research group at IDIBELL and the Bellvitge University Hospital, has obtained the position of Professor of Surgery at the University of Barcelona in the competition held on July 20.
Pancreatic beta-cell boost in mice paves way for future diabetes treatments
A research team from IDIBELL, CRG and UB has uncovered the role of a gene that is critical to boosting the number of insulin-producing cells during the early development of the pancreas. The findings could bolster diabetes research efforts and eventually lead to new replacement therapies for the disease.
Identified two new genes implicated in developmental brain diseases
Two studies with the participation of IDIBELL and the University of Barcelona have identified mutations in the CLCN3 gene, encoding a chloride transporter in endosomes, and the CHRM1 gene, corresponding to the M1 muscarinic neuronal receptor, as responsible for defects in brain development.
New advances in the characterization of the minority disease Limfangioleiomyomatosis
A team from IDIBELL and the ICO, through gene and protein expression analysis of the disease, has determined the biological traits that would explain the high heterogeneity and molecular similarities with cancer.
IDIBELL’s Innovation Unit receives the UNE 166002:2014 certification
The certification corroborates the conformity of the innovation management system according to the UNE 166002:2014 standard and certifies that IDIBELL is able to generate and manage innovation projects, systematize R+D+I activities and ensure that they are carried out effectively and efficiently.
Identified key alteration in the genes involved in the development of Cornelia de Lange syndrome
A study identifies the molecular basis of this rare disease, which causes extremities abnormalities and growth delay.
The immunological imprinting condition the response to SARS-CoV-2
A study by IDIBELL, Bellvitge Hospital, and the Icahn School of Medicine at Mount Sinai has shown for the first time that pre-existing immunity against other coronaviruses influences a possible immunity against SARS-CoV-2